News from our Team
Isakson SH, Rizzardi AE, Coutts AW, Carlson DF, Kirstein MN, Fisher J, Vitte J, Williams KB, Pluhar GE, Dahiya S, Widemann BC, Dombi E, Rizvi T, Ratner N, Messiaen L, Stemmer-Rachamimov AO, Fahrenkrug SC, Gutmann DH, Giovannini M, Moertel CL, Largaespada DA, Watson AL. "Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1." Communications Biology, Article number: 158 (2018).
Babiker HM, Byron SA, Hendricks WPD, Elmquist WF, Gampa G, Vondrak J, Aldrich J, Cuyugan L, Adkins J, De Luca V, Tibes R, Borad MJ, Marceau K, Myers TJ, Paradiso LF, Liang WS, Korn RL, Cridebring D, Von Hoff DD, Carpten JD, Craig DW, Trent JM, Gordon MS. "E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases." Invest New Drugs. 2018 Sep 28.
Hubbard ME, Arnold S, Bin Zahid A, McPheeters M, Gerard O'Sullivan M, Tabaran AF, Hunt MA, Pluhar GE. "Naturally Occurring Canine Glioma as a Model for Novel Therapeutics." Cancer Invest. 2018 Sept 20: 1-9.
Cong H, Zhao X, Castle BT, Pomeroy EJ, Zhou B, Lee J, Wang Y, Bian T, Miao Z, Zhang W, Sham YY, Odde DJ, Eckfeldt CE, Xing C, Zhuang C. "An indole-chalcone inhibits multidrug-resistant cancer cell growth by targeting microtubules." Mol Pharm. 2018 Jul 26. Epub ahead of print
Wu Y, Han B, Li Y, Munro E, Odde DJ, Griffin EE. "Rapid diffusion-state switching underlies stable cytoplasmic gradients in the Caenorhabditis elegans zygote." Proc Natl Acad Sci USA. 2018 Jul 24. Epub ahead of print.
Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF. "Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine." Pharm Res. 2018 Jul 12; 35(9):177.
Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F, Barriere C, Debussche L, Watters J, Tian S, Decker PA, Eckel-Passow JE, Kitange GJ, Johnson AJ, Parney IF, Anastasiadis PZ, Agar NYR, Elmquist WF, Sarkaria JN. "Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier." Mol Cancer Ther. 2018 Jul 3. Epub ahead of print.
Mike Olin, PhD was invited to speak in the Immuno-Oncology Targets track of the World Preclinical Congress (Boston) on June 21 in the session on "Novel Immune Checkpoints and Immunomodulatory Strategies." His talk was on "Targeting the CD200 Checkpoint Blockade: A New Avenue for Immunotherapy".
Pierpont EI, Hudock RL, Foy AM, Semrud-Clikeman M, Pierpont ME, Berry SA, Shanley R, Rubin N, Sommer K, Moertel CL. "Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1." J Neurodev Disord. 2018 Jun 18; 10(1): 21.
Chris Moertel, MD was featured on Kare11 on June 8 in a story titled "Teen cancer survivor volunteers for chemo to help others."
Graner MW, Schnell S, Olin MR. "Tumor-derived exosomes, microRNAs, and cancer immune suppression." Semin Immunopathol. 2018 Jun 4. Epub ahead of print.
Mike Olin, PhD; Liz Pluhar, DVM, PhD and Matt Hunt, MD were highlighted on the Rochester MN NBC affiliate in a story titled "Brain cancer clinical trials in dogs could speed up human trials" which discussed the UMN's CD200 research on May 30, 2018.
Chris Moertel, MD and Mike Olin, PhD were highlighted on the Love Your Melon blog where they discussed development of the next generation brain tumor vaccine that is slated to be tested in a clinical trial lat this year.
Walter Low, PhD was highlighted in the article "Can Zika fight cancer?" in the Spring 2018 issue of the University of Minnesota Foundation Legacy publication.
We had a very successful Fourth Minnesota Neuro-Oncology Symposium! Thanks to everyone who was able to attend and especially to all of our supporters of the event. View some photos of the event on our event page.
Hemmat M, Castle BT, Odde DJ. "Microtubule dynamics: moving toward a multi-scale approach." Curr Opin Cell Biol. 2018 Jan 16; 50: 8-13.
Ray A, Morford RK, Ghaderi N, Odde DJ, Provenzano PP. "Dynamics of 3D carcinoma cell invasion into aligned collagen." Integr Biol (Camb). 2018 Jan 17 (epub ahead of print).
Clark Chen, MD, PhD was highlighted in the news story "Breakthrough surgery uses laser to remove Minnesota man's brain tumor" on WCCO on January 8, 2018.
Clark Chen, MD, PhD was highlighted in the article "Oncolytic virus therapy passes early efficacy tests in glioma subtypes" on OncLive on January 7, 2018.
Clark Chen, MD, PhD was highlighted in the article "New technology, minimally invasive approach gives U of M brain tumor patient a second chance" on the Departmnet of Neurosurgery website on January 2, 2018.
Liz Pluahr, DVM, PhD received a new five-year canine cancer research grant funded as part of the 21st Century Cures Act by the National Cancer Institute. Read more in the article "Canine Brain Tumor Research May Speed Human Trials" posted on December 11, 2017 on the College of Veterinary Medicine website.
Mike Olin, PhD; Chris Moertel, MD; Elizabeth Neil, MD; and Clark Chen, MD, PhD were highlighted in the article "A cunning opponent: A University research team designs an immunotherapy to outsmart a challenging adversary--brain cancer" in the Fall 2017 issue of the Medical Bulletin from the University of Minnesota Medical School.
Liz Pluhar, DVM, PhD attended and presented a poster at the Society for Neuro-Oncology 22nd Annual Meeting in San Francisco, California on November 16-19, 2017.
William Elmquist, PhD attended and gave a talk at the Society for CNS interstitial Delivery of Therapeutics (SCIDOT) meeting in San Francisco, California on November 15-16, 2017.
October 20, 2017: Michigan Medicine Headlines posted an article titled "Clinical Trial will Treat Glioblastoma in Pet Dogs" which highlighted a new immunotherapy approach to brain cancer treatment in dogs. This work is a collaboration between Maria Castro, PhD and Pedro Lowenstein, MD, PhD, from Michigan Medicine along with Liz Pluhar, DVM, PhD and Michael Olin, PhD from the University of Minnesota.
Higham CS, Steinberg SM, Dombi E, Perry A, Helman LF, Schuetze SM, Ludwig JA, Staddon A, Milhem MM, Rushing D, Jones RL, Livingston M, Goldman S, Moertel C, Wagner L, Janhofer D, Annunziata CM, Reinke D, Long L, Viskochil D, Baker L, Widemann BC. "SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors." Sarcoma. 2017 Sep 12. Epub ahead of print.
Minnesota Monthly named Chris Moertel MD as "Top Doctor 2017"
Kyle Williams, PhD, postdoctoral fellow in David Largaespada's laboratory and past Cancer Biology Training Grant member, was named a Children's Tumor Foundation Young Investigator and awarded a two-year fellowship for the study of nervous system tumors associated with Neurofibromatosis Type 1.
Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Feng Y, Protter AA, Elmquist WF, Sarkaria JN. Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of poly (ADP-ribose) polymerase inhibition on temozolomide therapy in glioblastoma. Mol Cancer Ther. 2017 Sep 25. Epub ahead of print
Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF. "Is the blood-brain barrier really disrupted in all glioblastomas? - A critical assessment of existing clinical data." Neuro Oncol. 2017 Sep 7. Epub ahead of print.
Laramy JK, Kim M, Gupta SK, Parrish KE, Zhang S, Bakken KK, Carlson BL, Mladek AC, Ma DJ, Sarkaria JN, Elmquist WF. "Heterogeneous binding and CNS distribution of the multi-targeted kinase inhibitor ponatinib restrict orthotopic efficacy in a patient-derived xenograft model of glioblastoma." J Pharmacol Exp Ther. 2017 Aug 28. Epub ahead of print.
Michael Olin, Christopher Moertel, and G. Elizabeth Pluar were highlighted in the article "U of M Readies Clinical Trial for Promising Brain Cancer Drug Therapy" in the July 19, 2017 article in Twin Cities Business.
Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, Lassman AB, Chan TA, Yamada J, DeAngelis L, Ballangrud A, Young R, Panageas KS, Beal K, Omuro A. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy with Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. Int J Radiat Oncol Biol Phys. 2017 June 30. Epub ahead of print.
David Odde and David Largaespada were highlighted in the article "U professors work to engineer slower cancer cells" in the June 27, 2017 issue of the Minnesota Daily.
Diamond EL, Prigerson HG, Correa DC, Reiner A, Panageas K, Kryza-Lacombe M, Buthorn J, Neil EC, Miller AM, DeAngelis LM, Applebaum AJ. "Prognostic Awareness, Prognostic Communication, and Cognitive Function in Patients with Malignant Glioma." Neuro Oncology. 2017 June 22. Epub ahead of print.
Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF. "Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?" Pharmacological Research. 2017 June 17; 123:10-25.
Das P, Goyal T, Hunt MA. "Intrathoracic meningocele associated with neurofibromatosis Type 1 and a novel technique for surgical repair: case report." Journal of Neurosurgery: Spine. 2017 June 16: 1-4.
David Odde was highlighted in a video and article "New insight into how cancer spreads" on June 15, 2017 by Kare11.
Lester Drewes was highlighted in the article "Lecture subject: 'Chemo brain'" in the June 12, 2017 issue of the Duluth News Tribune.
David Largaespada served on the review committee to score the basic science abstracts at the 2017 Children's Tumor Foundation Neurofibromatosis Conference, June 10-13 2017 in Washington D.C.
Oral Presentations from members at Children's Tumor Foundation Neurofibromatosis Conference:
- Exploiting novel vulnerabilities in NF1-associated tumorigenesis: A small molecule screen identifies compounds capable of selectively killing NF1 deficient human Schwann cells.
- Kyle B Williams PhD1, Rory L Williams BS1, Sam A Finnerty BS1, Adrienne L Watson PhD2, Sue Rathe PhD1, Jon Hawkinson PhD1, Gunda Georg PhD1, Christopher L Moertel MD1, David A Largaespada PhD1, 1University of Minnesota, 2Recombinetics Inc.
- A Swine Model of Neurofibromatosis Type I
- Adrienne L Watson PhD2, Sara Isakson DVM1, Alex Coutts BS2, Kyle Williams PhD1, Rory Williams BS1, Daniel F Carlson PhD2, Christopher L Moertel MD1, Scott C Fahrenkrug2, David A Largaespada PhD1, 1University of Minnesota, 2Recombinetics Inc.
- NF1 Associated Dystrophic Scoliosis: Standardization of Diagnostic Criteria and Prediction Using Single-Nucleotide Polymorphism Markers
- Christopher L Moertel MD1, David W Polly1, Ann M Brearley1, Alvin H Crawford2, Daniel J Sucato3, Leah Carreon4, A Noelle Larson5, David Stevenson6, Michael Vitale7, Charles Ledonio1, 1University of Minnesota, 2University of Cincinnati, 3Texas Scottish Rite Hospital (UT Southwestern), 4University of Louisville, 5Mayo Clinic, 6Lucile Packard Children's Hospital Stanford, 7Columbia University.
Poster Presentations from members at Children's Tumor Foundation Neurofibromatosis Conference:
- Perturbation of the Hyaluronan-Rich Nerve Sheath Tumor Microenvironment to Improve Drug Efficacy and Delivery
- Bryant J Keller BS1, Adrienne Watson PhD2, Kyle Williams PhD1, Rory Williams BS1, Leah Anderson BS1, Marjorie Carlson BS1, Justin Knight BS1, Colleen Forster BS3, Kwangmin Choi BS4, Nancy Ratner PhD4, Co-Senior: Paolo Provenzano PhD1, Co-Senior: David Largaespada PhD1. Affiliations: 1University of Minnesota, 2Recombinetics Inc., 3BioNet, 4Cincinnati Children's Hospital
- The University of Minnesota Experience with Bevacizumab for Treatment of NF2-Associated Vetibular Schwannomas
- Christopher L Moertel MD, Pavlina Sverak, Samuel C Levine, Meredith E Adams, Tina C Huang, Stephen J Haines, Katherine Sommer; University of Minnesota.
Several members of the University of Minnesota Brain Tumor Program attended the Annual Step Up for NF Fundraiser Walk hosted by NF Upper Midwest on Saturday, June 17, 2017 at Lake Como.
Mekhdjian AH, Kai F, Rubashkin MG, Prahl LS, Przybyla LM, McGregor AL, Bell ES, Barnes JM, DuFort CC, Ou G, Chang AC, Cassereau L, Tan SJ, Pickup MW, Lakins JN, Ye X, Davidson MW, Lammerding J, Odde DJ, Dunn AR, Weaver VM. "Integrin-mediated traction force enhances paxillin molecular associations and adhesion dynamics that increase the invasiveness of tumor cells into a three-dimensional extracellular matrix." Molecular Biology of the Cell 2017 June 1; 28(11): 1467-1488.
Bangasser BL, Shamsan GA, Chan CE, Opoku KN, Tuzel E, Schlichtmann BW, Kasim JA, McCullough BR, Rosenfeld SS, Odde DJ. "Shifting the optimal stiffness for cell migration." Nature Communications 2017 May 22; 8: 15313.
Mike Olin, PhD invited to give the Neurosurgery Grand Rounds at the University of Colorado, Anschutz Medical Campus on May 9th. "Targeting the CD200 Checkpoint Blockade: A New Avenue for Immunotherapy"
Klank RL, Decker Grunke SA, Bangasser BL, Forster CL, Price MA, Odde TJ, SantaCruz KS, Rosenfeld SS, Canoll P, Turley EA, McCarthy JB, Ohlfest JR, Odde DJ. "Biphasic Dependence of Glioma Survival and Cell Migration on CD44 Expression Level." Cell Reports 2017 April 18; 19(3): 668.
The University of Minnesota Foundation wrote two articles about brain tumor research at the University:
- "Try, try again" about brain cancer immunotherapy developed by the U's Michael Olin, PhD and Liz Pluhar, DVM, PhD.
- "Predicting cancer's next move" about Paolo Provenzano, PhD and David Odde, PhD and the work they are doing with physics-based research.
Randy Shaver Cancer Research & Community Fund announced their latest recipients of grant awards, with the following going to members of our group:
- Walter Low, PhD: Harnessing the Zika virus for selectively killing brain tumors
- Michael Olin, PhD: Targeting activation receptors to overcome tumor induced immunosuppression
- Chris Pennell, PhD: Protecting the brain from cancer-killing cells
The University of Minnesota group of researchers that are one of three consortia for the Children's Tumor Foundation Synodos for NF1 were highlighted in a video on the CTF website.
Gampa G, Vaidhyanathan S, Resman BW, Parrish KE, Markovic SN, Sarkaria JN, Elmquist WF. "Challenges in the delivery of therapies to melanoma brain metastases." Current Pharmacology Reports 2016 Dec; 2(6): 309-325.
Minnesota Monthly named Chris Moertel MD as "Top Doctor 2016"
Minneapolis St Paul Magazine named Chris Moertel MD as "Top Doctor" for the 6th year.
Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, Wiesner SM. "Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency." Haematologica. 2016 Oct; 101(10): 1190-1199.
Morrissy AS, Largaespada DA, et al. "Divergent clonal selection dominates medulloblastoma at recurrence." Nature. 2016 Jan 21; 529(7586): 351-357.
Minneapolis St Paul Magazine named Chris Moertel MD as "Top Doctor" for the 5th year.
Xiong Z, Ampudia-Mesias E, Shaver R, Horbinski CM, Moertel CL, Olin MR (2015). "Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy." Immunotherapy 8(9): 1059-1071.
Parrish KE, Pokorny J, Mittapalli RK, Bakken K, Sarkaria JN, Elmquist WF (2015). "Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model." J Pharmacol Exp Ther 355(2): 264.271.